Markets · Global Equities · US
AbCellera Biologics Inc. ABCL
Exchange Nasdaq. Sector Pharma & biotech. Source: SEC companyfacts. Not a price feed.
- Revenue TTM 38.40M
- EBITDA TTM -221.61M
- Net debt -119.88M
- ND/EBITDA 0.54
- EBITDA/interest —
- ROE -0.21
- Implied band BB